

How to cite this article: Hosseini K, Ahangari H, Chapeland-leclerc F, Ruprich-Robert G, Tarhriz V, Dilmaghani A. Role of Fungal Infections in Carcinogenesis and Cancer Development: A Literature Review. *Advanced Pharmaceutical Bulletin*, doi: 10.34172/apb.2022.076

Role of Fungal Infections in Carcinogenesis and Cancer Development: A Literature Review

Running title; Carcinogenesis of fungal infections

Kamran Hosseini ^{1,2}, Hossein Ahangari ³, Florence Chapeland-leclerc ⁴, Gwenael Ruprich-Robert ⁴, Vahideh Tarhriz ^{5*}, Azita Dilmaghani ^{6,7*}

¹ Department of Molecular Medicine, Faculty of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran

² Student research committee, Shiraz University of Medical Sciences, Shiraz, Iran.

³ Department of Food Science and Technology, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.

⁴ Université de Paris, Faculté des Sciences, Laboratoire Interdisciplinaire des Energies de Demain (LIED), UMR 8236 CNRS, F-75013, Paris, France.

⁵ Molecular Medicine Research Center, Bio-medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran

⁶ Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

⁷ Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

Vahideh Tarhriz: <https://orcid.org/0000-0002-3018-9313>

Correspondences:

Azita Dilmaghani, Ph.D

Email: dilmaghani.a@gmail.com

Tel: +989141035048

Vahideh Tarhriz, Ph.D

Email: t.tarhriz@yahoo.com

Tel: +989142575057

Abstract

Cancer is a serious debilitating disease and one of the most common causes of death. In recent decades the high risk of various cancers enforced scientists to discover novel prevention and treatment methods to diminish the mortality of this terrifying disease. Accordingly, its prevention can be possible in near future. Based on epidemiological evidence, there is a clear link between pathogenic fungal infections and cancer development. This association is often

seen in people with weakened immune systems such as the elderly and people with acquired immunodeficiency (AIDS). Carcinoma in these people is first seen chronically and then acutely. Although the different genetic and environmental risk factors are involved in carcinogenesis, one of the most important risk factors is fungal species and infections associating with cancers etiology. Now it is known that microbial infection is responsible for initiating 2.2 million new cancer cases. In this way, many recent studies have focused on investigating the role and mechanism of fungal infections in diverse cancers occurrence. This review provides a comprehensive framework of the latest clinical findings and the association of fungal infections with versatile cancers including esophageal, gastric, colorectal, lung, cervical, skin, and ovarian cancer.

Keywords: Cancer; Fungi; Infection; Carcinogenesis; Fungal species

1- Introduction

Diseases triggered by excessively dividing of the tissue cells that can develop into intrusive lumpy masses is called cancer, which also is mentioned to as tumors. About 200 types of cancers in human kind are currently established by the National Cancer Institute (<http://www.cancer.gov/types>) and among them, some cancers can spread from their origin to other body tissues in a process so-called metastasis. Cancers classification is based on the tissue and/or organ of the origin e.g. carcinomas that refers to the cancers which arise in tissues or cover body organs. Also, other classes like melanomas, sarcomas, leukemia and lymphomas, are other known kinds of cancers.¹

The cancer Tsunami is going to be more expanded. For instance, 150000 new cases of colorectal cancers (CRC) are identified annually in the US. So, the studies have been focused on exploring the risk factors of different cancers to drop the incidence of them. Every kind of the cancers is affected by special risk factors, e.g., history of IBD (Inflammatory bowel disease), Type 2 diabetes and family history that are the main risk factors of CRC.^{2,3} It is noticeable that there will be increased incidence, approximately 50%, and near 17 million deaths by 2030 and this fact stress the necessity of discovering the more selective treatments for cancers based on their originating factor especially for the cancers triggered by microbial infections to diminish the unintended harmful outcomes on healthy tissues.⁴

Risk factors involved in cancers can vary by the area and country parallel to overall cancer incidence and mortality arises. Factors including age, smoking, diet and fat saturated regimes, body weight, alcohol consumption, exposure to pollutants and/or radioactivity, genetic background, and the infection by bacterial and fungal species have been coupled to the risk of carcinogenesis and versatile types of cancers (Figure 1). The studies revealed that infection by microbial species as a risk factor, is responsible for initiating of 2.2 million new cancer cases.⁵ Nowadays, it is estimated that around 16% of the overall cancer incidences is associated to microbial infections and toxicities. On the other hand, it is proposed that the microbial infection not only can boost the cancer risk but can also assist its treatment.⁶

Invasive fungal infections (IFI) maintain to pose a challenge in cancer development and are linked with a high incidence of mortality and morbidity. By the last 20 years, despite the development of numerous diagnostics and therapeutic in the field of fungal infections, the IFI mortality have sustained to 35.7% growth. This means that the cancer growth rate is probably affected by IFI and it's needed to be scrutinized.⁷ The most common genera and species of fungi involved in cancers are *Candida albicans*, *C. glabrata*, *C. tropicalis*, *Aspergillus flavus*, *A. parasiticus*, *Fusarium verticillioides* and *F. proliferatom*. Nevertheless, continuous efforts to distinguish the association between the cancers and fungal infections should be nonstop since it is not expected that the combat against cancer to be won soon (Figure 2).⁸

In the present review, the role of opportunistic and pathogenic fungal infections with carcinogenesis of various organs, especially solid organs has been reviewed based on the latest clinical research studies and the most up-to-date scientific articles published in databases including pubmed and scopus. Before this review, there was no complete report on the relationship between fungi and carcinogenesis of solid organs; however, the current study has thoroughly investigated the gap between the role of different fungi and carcinogenesis.

2-The role of fungal infections in esophageal cancer

Esophageal carcinoma (EC) is the sixth leading cause of cancer-related mortality and the eighth leading cause of cancer worldwide. The disease is more prevalent in men,⁹ but in most countries of the world, the incidence rate per 100,000 people affects 2.5-5 men and 1.5-2.5 women.¹⁰ Histologically, the disease is classified into two categories: esophageal adenocarcinoma (EAC), which affects the lower esophagus, and esophageal squamous cell carcinoma (ESCC), which affects the middle and upper esophagus¹¹. Numerous risk factors for this type of cancer have been reported, including smoking, alcohol consumption, consumption of hot beverages and foods, poor nutrition, exposure to chemicals, environmental pollutants and radiation, and exposure to pathogenic and opportunistic microorganisms.¹²⁻¹⁴ In addition, various fungal infections can arise for EC, the most common fungus is *Candida* spp., which is an opportunistic yeast that colonizes the mucosa of the genitourinary and gastrointestinal tract of healthy people (about 30-50% of people) without causing infection. *Candida* mostly occurs during the immune system suppression which manifests by skin, nails, and mucosa (esophagus) signs. In relation to mucus, this yeast causes chronic mucocutaneous candidiasis (CMCD).¹⁵ The most common genera and species of candida associated with candidiasis are the following: *Candida albicans*, *C. glabrata*, *C. tropicalis*,¹⁶ *C. krusei*, *C. parepsilosis*, *Torulopsis glabrata*, *T. tomata*, *Aspergillus flavus*, *A. parasiticus*, *Fusarium verticillioides*, *F. proliferation*¹⁷⁻²⁰. According to a study by Sara *et al.* (2016), in patients with primary immunodeficiency (PIDs), esophageal candidiasis occurs in cancer patients as CMCD with persistent or recurrent thrush. CMCD is caused by at least five mutations that ultimately affect the IL-17 pathways; One of these is a mutation in the AD (autosomal dominant) gene gain of function of the STAT 1 signaling protein, in which a genetic defect intensifies Th1 immune responses and ultimately reduces the production of IL-17 and IL-22.²¹ In another study, Mauricio *et al.* examined a patient with CMC (chronic mucocutaneous candidiasis) who had decades of treatment-resistance esophageal candidiasis and eventually developed epidermoid esophageal cancer. In this patient, modulation of immune function induced by mitogen suppression and antigen-induced lymphoproliferation disrupted NK cytotoxic activity and IL-2 secretion, resulting in increased IL-4 secretion and lymphocyte apoptosis.²²

3- The role of fungal infections in gastric cancer

Gastric cancer (GC) is the fourth leading cause of malignancy and the second leading cause of mortality in all malignancies worldwide^{23,24}. The five-year survival rate is 90% in Japan and 10-30% in European countries. Due to the incidence of GC, more than fifty percent of new cases occur in developing countries.^{25,26} Gastric cancer is generally classified into four categories: Sporadic gastric cancer (SGCs),²⁷ Early onset gastric cancer (EOGC),²⁷ gastric stump cancer (GSC),²⁸ and Hereditary diffuse gastric cancer (HDGC).²⁹ Risk factors for this cancer include: smoking,³⁰ alcohol consumption,³¹ obesity,³² pernicious anemia and blood type A,³³ mycotoxins³⁴ and *Helicobacter pylori* infection.³⁵

Preliminary studies based on culture-dependent methods have shown that fungi make up about 70% of the digestive system of adults and their number is in the range of 10^2 .³⁶ The presence

of some fungi can contribute to development of GC, including *C. albicans*,³⁷ *Phialemonium* spp.,³⁸ *Aspergillus* spp., *Penicillium* spp., and *Fusarium* spp.³⁹ But in general, number of commensal fungal species are predominant in the gastrointestinal tract, including *S. cerevisiae*, *Malassezia* spp., and some species are classified as transient microbiota, e.g *Aspergillus* spp., *Mucor* spp., *Cryptococcus* spp., *Rhodotorula* spp., *Trichosporon* spp., *Histoplasma* spp., *Coccidioides* spp., *Paracoccidioides* spp. and *Blastomyces* spp.^{40,41} Among these fungi, there is ample evidence that *C. albicans* is able to initiate and develop cancerous events through several mechanisms: 1. Production of carcinogens such as acetaldehyde, which contribute to the progression of cancer (*C. albicans*, *C. tropicalis*, *C. parapsilosis* produce more acetaldehyde than other species of *Candida*).⁴¹ 2. Induction of inflammatory processes that contributes to tumor metastasis (using cytokines such as CXCL1, CXCL2, CXCL3, TNF- α , and IL-18 facilitates tumorigenesis, angiogenesis, and metastasis).^{34,42-45} 3. Processes related to molecular mimicry (molecular mimic of the protein associated with complement receptor 3 (CR3-CP) *Candida albicans* that supports cancer progression).⁴⁶ 4. The Th17 response (Th17 is a subset of CD4 + T cells that are active in response against *C. albicans*, and another cytokine from the Th17 family, IL-23, increases angiogenesis and tumor growth, and antagonizes IL-12 and IFN.^{47,48} Another study showed that 54.2% of patients with gastric ulcer and 10.3% of patients with chronic gastritis had candidiasis, which was evident in 20% of patients with gastric cancer.^{49,50}

4- The role of fungal infections in colorectal cancer

Colorectal cancer (CRC), the most common type of cancer worldwide, is the third leading cause of cancer and the fourth leading cause of cancer deaths, with a mortality rate of about 700,000. Overall, CRC accounts for 11% of all diagnosed cancers.⁵¹ By 2018, about 1.8 million new cases of CRC have been reported.² The incidence of CRC in men is about 19.7 and in women 23.6 per 100,000 people and it is more common in developed countries.⁵² The mortality rate until 2018 was about 881,000.² In general, mutations in oncogenes, tumor suppressor genes, and genes involved in DNA repair are associated with the development of CRC, and according to the primary origin of the mutation, CRCs are classified into three categories: *sporadic* (Most point mutations cause this type of CRC and occur in the genes APC (Adenomatous Polyposis Coli), kRAS, Tp53, and DCC),⁵³ *hereditary* (Most point mutations occur in another allele of the mutated gene, and this inherited form is divided into two groups: FAP (Familial Adenomatous Polyposis) and HNPCC (Hereditary non-polyposis colorectal cancer due to mutations in DNA repair proteins such as MSH2, MLH1, MLH6, PMS1, and PMS2 occur),^{54,55} and *familial*. Environmental and hereditary risk factors play an important role in the development of CRC. CRC risk factors are classified into two categories: non-modifiable risk factors such as race,⁵⁶ sex and age,² inflammatory bowel disease (IBD),⁵⁷ cystic fibrosis,⁵⁸ and cholecystectomy⁵⁹ as well as modifiable risk factors such as obesity,⁶⁰ diet,⁶¹ smoking and alcohol,⁶² and diabetes and resistance to insulin.⁶³

The role of fungal agents in CRC has not been well understood due to low frequency and lack of reference genome, but using high-throughput sequencing methods, they have been able to identify several fungal species,⁶⁴ and recently their role in IBD has been proven.⁶⁵ Among the fungi that are associated with CRC, the following can be mentioned: *Candida* genus such as *C. tropicalis* and *C. albicans*, *Phoma*,⁶⁶ *Malassezia*,⁶⁷ *Trichosporon*,⁶⁸ *Cladosporium*⁶⁹ and so on. In addition to the above, fungi such as *Paracoccidioides*, *Histoplasma*, *Cryptococcus*, *Aspergillus*, *Penicillin*, *Zygomycetes*, *Pneumocystis*, *Scedosporiosis* cause colonic involvement and may eventually be involved in CRC formation.⁷⁰ In this regard, a number of studies have revealed the relationship between fungal agents and CRC. According to a study by Luan *et al.*,

they examined fungal microbiota of biopsy specimens from intestinal adenomas and adjacent tissues using the deep sequencing technique and found that 45% of fungal microbiota contained the opportunistic pathogen *Candida* and *Phoma* and approximately 1% *Cladosporium*, *Trichosporon*, *Rhodotorella*, *Thanatephorum*, and *Plectosphaerella*.⁶⁶ In another study by Gao in 2017, it was found that the ratio of ascomycota to basidiomycota was different in the three groups of control, polyp, and CRC, so that ascomycota has a frequency of 37-54% and basidiomycota 5-4%.⁷¹ In 2019, Coker *et al.* also examined colonic fungal microbiota, which are used as diagnostic markers for CRC, such as *A. flavus*, *Kwoniella mangrovensis*, *Pseudogymnoascus* sp. VKM F-4518, *Debaryomyces fabryi*, *A. sydowii*, *Moniliophthora pernicioso*, *K. heavenensis*, *A. ochraceoroseus*, *Talaromyces islandicus*, *Malassezia globosa*, *Pseudogymnoascus* sp. VKM F-4520, *A. rambellii*, *Pneumocystis murina* and *Nosemia apis* and also found fungi such as *Malassezia*, *Moniliophthora*, *Rhodotorula*, *Acremonium*, *Thielaviopsis* and *Pisolithus* is associated with CRC.⁷²

5- The role of fungal infections in lung cancer

Lung cancer (LC) is one of the most common causes of cancer death in the world. LC incidence is 1.35 million new cases (representing 12.4% of all new cancer cases) and mortality is 1.18 million deaths (accounting for 17.6% of the global total).²⁶ The five-year survival rate in newly diagnosed LC is 15%.⁷³ Men are more likely to develop LC than women, and it affects more African American men.⁷⁴ One of the major causes of LC is disruption of the molecular pathways of the lung cell, which alters normal cell growth, differentiation, and apoptosis.⁷⁵ In general, LC is pathologically present in two forms: NSCLC (non-small cell lung carcinoma) (85% of cases) and SCLC (*small-cell lung carcinoma*) (15% of cases).⁷⁶ Many internal and external factors are considered as risk factors of LC, including smoking, arsenic in drinking water, radioactive radon gas, asbestos, tuberculosis, COPD, HIV infection,⁷⁷ and mutations in genes EGFR,⁷⁸ BRAF,⁷⁹ KRAS,⁸⁰ and so on. As mentioned, one of the risk factors for LC is people with immunocompromised systems who become susceptible to lung disease and eventually LC by exposure to opportunistic fungi such as *Aspergillus* sp., *Cryptococcus* sp., *Pneumocystis* sp. and endemic fungi.⁸¹ For example, in opportunistic IPA (invasive pulmonary aspergillosis), people with immunocompromised systems are susceptible to *Aspergillus* and *Cryptococcus* and pose a serious threat to people with cancer.⁸² Thus, the differential diagnosis of LC solid tumors has revealed types of fungi such as *Trichosporon*, *Fusarium*, *Rhizopus*, *Histoplasma capsulatum*, *H. immitis*, and *Cryptococcus neoformans*. It has been shown that in patients with LC who receive corticosteroids, they open the way for the entry of opportunistic pathogens such as *Aspergillus* and *P. jiroveci* and exacerbate the disease.⁸³ Another study reported that the dimorphic and opportunistic fungal pathogen *T. marneffeii*, the causative agent of talaromycosis, causes lung infections in people with immunocompromised systems. Following a study by Lopez *et al.*, (2020) A 56-year-old HIV-free woman was reported to have talaromycosis and co-infected with stage IV NSCLC. The patient received liposomal amphotericin B but she died due to a decrease in blood oxygen levels as well as a decrease in the level of blood cells.⁸⁴ Another study by Watanabe was conducted in 2019 on a 69-year-old man who underwent chemoradiotherapy due to LC but later developed SIPA (subacute invasive pulmonary aspergillosis), a disease caused by *A. fumigatus*, due to immunocompromised system. For the treatment of fungal infections, he received amphotericin B in combination with voriconazole.⁸⁵

6- The role of fungal infections in cervical cancer

Cervical cancer (CC) is the third most common cancer of the female reproductive system in the world.⁸⁶ According to a 2012 report, the standard rate for cervical cancer is about 14 cases per 100,000 people.⁹ In general, by 2018, about 530,000 women were diagnosed with CC, of which 257,000 died.⁸⁷ The incidence of CC is higher in African and South Asian countries, and its incidence and mortality vary in most parts of the world. As a result, developed countries account for 86% of all CC cases and 88% of all CC deaths.^{24,87} The incidence rate of CC in Iran is about 2.61 per 100,000 people.⁸⁸ The five-year survival rate in developed countries is about 66%.⁸⁹ There are a number of risk factors for CC, including: reproductive factors, obesity, sexual behavior, diet, multiparity, prolonged use of hormonal contraceptives, poor socioeconomic status, smoking, Multiple pregnancies, and finally the presence of bacterial, viral and fungal infectious agents.⁹⁰ A 2018 study identified several fungi from the cervicovaginal region, including *Candida*, *Malassezia*, *Sporidiobolaeae*, *Saccharomyces*, *Nakaseomyces*, *Gjaerumia*, and *Pleosporales*.⁹¹ According to a study by Moradi et al. In Iran (2015), one of the important fungi that is the link between cervicovaginal infections and cervical cancer was *C. albicans*, which was reported in women with high socioeconomic status in Bandar Abbas.⁹² In 2015, Rajane studied a 42-year-old woman who had received immunosuppressive therapy for cervical neoplasia and developed fungemia due to *Cryptococcus laurentii* with a weakened immune system and was eventually treated with fluconazole.⁹³

7- The role of fungal infections in skin cancer

Skin cancer (SC) is one of the most common types of cancer among white populations and is generally classified into two categories: melanoma and non-melanoma (NMSC).⁹⁴ According to the latest statistics from 2020, the number of new cases of skin cancer is estimated at 108420 people and the approximate number of deaths is about 11480 people.⁹⁵ Remember that the increase in melanoma incidence is not parallel to the increase in mortality rates. NMSC, which includes Bowens disease, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC), is more prevalent among Caucasian populations.⁹⁶ Increased incidence of SC is associated with several factors including UV exposure, light skin (albinism), old age, male gender, chemicals (such as arsenic), radiation exposure, XP, Weakened immune system, smoking, and viral (HPV) and fungal infections.⁹⁷ Fungal infections have been shown to occur more frequently in people with weakened immune systems. Initially, most fungal infections were due to the presence of *Candida* species, but recently it has been shown that the frequency of *Aspergillus* sp. is increasing.⁹⁸ In general, two types of fungal infections are involved in skin cancer: infections caused by pathogenic fungi such as *C. neoformans*, *H. capsulatum*, *C. immitis*, *Trichosporon spp.* Etc., as well as opportunistic fungi such as *Candida* sp. (eg *C. albicans*, *C. tropicalis*, *C. glabrata*, *C. parapsilosis*), *Aspergillus*, *Mucorales*, *Fusarium*, *Rhizopus*.⁹⁹ As mentioned, opportunistic fungal infections cause disease in people with weakened immune systems. In this regard, Pulido et al. in 2018 studied solid organ transplant recipients (SOTR) in such a way that by immunosuppression, graft survival is increased and this factor causes skin cancer and a variety of infections, followed by Those opportunistic infections are caused by black filamentous fungi (pheochromycosis) such as *A. alternata*, *A. infectoria*, *C. cladosporioides*, *M. arundinis*, and *E. oligosperma*.¹⁰⁰ Another study was conducted in 2016 by Brothers et al. on a 61-year-old man whose immune system was suppressed due to receiving chemotherapy drugs for multiple myeloma. Following the injury, his finger became sore with a rose thorn and despite the weak immune system, the wound developed and squamous cell carcinoma developed and *C. parapsilosis* was isolated from the patient.¹⁰¹

8- The role of fungal infections in ovarian cancer

Ovarian cancer (OC) is the seventh most common type of cancer in women in the world and after breast cancer is the second most common type of cancer in women over 40 (in a developed country).^{102,103} The highest incidence rates are observed in Eastern and Southern Europe and the lowest rates are observed in China.¹⁰⁴ The five-year survival rate in the early stages of OC is about 29%, but when the tumor progresses it reaches about 92%.¹⁰⁵ According to the latest statistics by 2020, the number of new OC cases is estimated at 21,750 and the number of deaths estimated at 13,940.⁹⁵ Pathologically, OC is divided into three categories: epithelial OC (90% of cases), stromal OC (5-6% of cases), and genital OC (2-3% of cases).¹⁰⁶ OC-related risk factors include: Reproductive risk factors (such as continuous ovulation)¹⁰⁷ and hormonal factors (such as gonadotropins),¹⁰⁸ family history and genetic predisposition (such as mutations in genes BRCA1, BRCA2 and MMR),¹⁰⁹ ethnicity and race (such as Jews, Dutch, and French Canadians), diet (fiber and vitamin low D intake),¹¹⁰ lactation,¹¹¹ obesity,¹¹² smoking¹¹³ and alcohol consumption.¹¹⁴ Although fungal infections are not a risk factor for OC, a research team in 2017 studied the association between OC and fungal infections. According to the study, the following fungi were found in cancer samples: *Pneumocystis*, *Acremonium*, *Cladophialophora*, *Malassezia*, *Microsporidia Pleistophora*, *Ajellomyces*, *Aspergillus*, *Candida*, *Cladosporium*, *Coccidioides*, *Cryptococcus*, *Cunninghamella*, *Issatchenkia*, *Nosema*, *Paracoccidioides*, *Penicillium*, *Pleistophora*, *Rhizomucor*, *Rhizopus*, *Rhodotorula*, *Trichophyton*.¹¹⁵

9. Result and Discussion

From the literature, it appears that fungal infections may play a significant role in the risk for precancerous lesions. The most common fungal species involved in cancers development are *Aspergillus flavus*, *A. parasiticus*, *Fusarium proliferatom*, *F. verticillioides*, *Candida albicans*, *C. tropicalis*, and *C. glabarata*.¹¹⁵ Furthermore, the ability of fungal species in carcinogens production such as acetaldehyde, nitrosamine, mycotoxins, and the generation of proinflammatory cytokines, can be risk factors in the promotion of various cancers.²⁶ Moreover, the potential role of fungal infections in oncogenic processes is the subject of debate in recent surveys of this topic. There are suggestions that fungal infection is a cause of cancers development possibly when the infection is chronic and connected to risk factors such as alcohol, tobacco, and etc.; however, each class of cancer is influenced by different risk factors, such as family history, Type 2 diabetes, and obesity, which are the main risk factors of cancer.^{50,52}

Along with the increased incidence of cancer associated with fungal infections more thorough surveys of the epidemiology of cancer patients with fungal infections can help to determine which patients are most likely to be infected. Therefore, superior monitoring and diagnostic efforts can expand the accuracy of diagnosis of fungal infection and will increase patient outcomes by permitting intervention at an earlier stage of invasive cancers.^{2,3} The value of controlled clinical studies of patients with fungal infections will greatly increase our knowledge of the most operative methods of treating disseminated cancer disease in immune-compromised cancer patients.

10- Conclusion

Several specific fungi are associated with carcinogenesis (Table 1). Recent studies indicated that the pathogenic fungal populations were increased in cancerous patients. It has been shown that the development of carcinogenesis is closely related to a fungal profile. The most common genera of fungi that contribute to the development of versatile cancers are *Candida* sp.,

Aspergillus sp., and *Fusarium* sp. causing an inflammation and consequently contributing to the progression of various cancers. Although, the link between infectious fungi and carcinogenesis is not undeniable, we cannot restrict to the study of fungal microbiota. In fact, we need to explore the intimate connections that could exist with fungi and their possible role on carcinogenesis through their effect on the varied and complex immune system. It seems that the manipulation of fungal profile can be a helpful approach in the rapid improvement of patients after anti-cancer treatment. Therefore, the focus on the potential effect of infectious fungi on the initiation of cancers and consequently the treatment of fungal infectious disease as a global approach is indispensable to predicate the possible subsequences of our current public health strategies.

Acknowledgment

The authors acknowledge Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran and Université de Paris, Faculté des Sciences, Paris, France.

Declaration of interest

All authors indicated that they have no conflicts of interest to disclose and are aware of its submission.

Funding:

This work was supported and funded scheme by Tabriz University of Medical Sciences (PharmD. Thesis).

References:

1. Ashu EE, Xu J, Yuan Z-C. Bacteria in cancer therapeutics: a framework for effective therapeutic bacterial screening and identification. *J Cancer* 2019;10(8):1781. doi:10.7150/jca.31699
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68(6):394-424. doi: 10.3322/caac.21492
3. Macrae FA. Colorectal cancer: Epidemiology, risk factors, and protective factors. *Clin Colon Rectal Surg*. 2005 Aug; 18(3): 133–140. doi: 10.1055/s-2005-916274
4. Sedighi M, Zahedi Bialvaei A, Hamblin MR, Ohadi E, Asadi A, Halajzadeh M, et al. Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. *Cancer Med* 2019;8(6):3167-81. doi: 10.1002/cam4.2148
5. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. *Lancet Glob Health* 2016;4(9):e609-e16. doi: 10.1016/S2214-109X(16)30143-7
6. Eyvazi S, Vostakolaei MA, Dilmaghani A, Borumandi O, Hejazi MS, Kahroba H, et al. The oncogenic roles of bacterial infections in development of cancer. *Microb Pathog* 2020;141:104019. doi: 10.1016/j.micpath.2020.104019
7. Krishnan N. Emerging fungal infections in cancer patients-a brief overview. *Med Mycol* 2016;2:16. doi: 10.21767/2471-8521.100016.
8. Chapeland-Leclerc F, Dilmaghani A, Ez-Zaki L, Boissard S, Da Silva B, Gaslonde T, et al. Systematic gene deletion and functional characterization of histidine kinase phosphorelay receptors (HKRs) in the human pathogenic fungus *Aspergillus fumigatus*. *Fungal Genet. Biol* 2015;84:1-11. doi: 10.1016/j.fgb.2015.09.005

9. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136(5):E359-E86. doi: 10.1002/ijc.29210
10. Chang F, Syrjänen S, Wang L, Syrjänen K. Infectious agents in the etiology of esophageal cancer. *Gastroenterology* 1992;103(4):1336-48. doi: 10.1016/0016-5085(92)91526-a
11. Bollschweiler E, Hölscher AH, Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. *Future Oncol* 2010;6(1):25-35. doi: 10.2217/fon.09.133
12. Kumagai N, Wakai T, Akazawa K, Ling Y, Wang S, Shan B, et al. Heavy alcohol intake is a risk factor for esophageal squamous cell carcinoma among middle-aged men: A case-control and simulation study. *Mol Clin Oncol* 2013;1(5):811-6. doi: 10.3892/mco.2013.142
13. Andrici J, Eslick GD. Hot food and beverage consumption and the risk of esophageal cancer: a meta-analysis. *Am J Prev Med* 2015;49(6):952-60. doi: 10.1016/j.amepre.2015.07.023
14. Chen Y, Tong Y, Yang C, Gan Y, Sun H, Bi H, et al. Consumption of hot beverages and foods and the risk of esophageal cancer: a meta-analysis of observational studies. *BMC Cancer* 2015;15(1):449. doi: 10.1186/s12885-015-1185-1
16. Takahashi Y, Nagata N, Shimbo T, Nishijima T, Watanabe K, Aoki T, et al. Long-term trends in esophageal candidiasis prevalence and associated risk factors with or without HIV infection: lessons from an endoscopic study of 80,219 patients. *PLoS One* 2015;10(7):e0133589. doi: 10.1371/journal.pone.0133589. eCollection 2015
17. MING-XIN L, MING-HSIN L, SHU-JUN C. Carcinogenesis of esophageal cancer in linxian, china. *Chinese medical journal* 1984;97(5):311-7.
18. Chauhan NM, Washe AP, Minota T. Fungal infection and aflatoxin contamination in maize collected from Gedeo zone, Ethiopia. *SpringerPlus* 2016;5(1):753. doi: 10.1186/s40064-016-2485-x
19. Marin S, Ramos A, Cano-Sancho G, Sanchis V. Mycotoxins: Occurrence, toxicology, and exposure assessment. *Food Chem Toxicol* 2013;60:218-37. doi: 10.1016/j.fct.2013.07.047
20. Omurtag GZ. Fumonisin, trichothecenes and zearalenone in cereals. *Int J Mol Sci* 2008;9(11):2062-90. doi: 10.3390/ijms9112062
21. Koo S, Kejariwal D, Al-Shehri T, Dhar A, Lilic D. Oesophageal candidiasis and squamous cell cancer in patients with gain-of-function STAT1 gene mutation. *United European Gastroenterol J* 2017;5(5):625-31. doi: 10.1177/2050640616684404
22. Domingues-Ferreira M, Grumach AS, Duarte AJDS, De Moraes-Vasconcelos D. Esophageal cancer associated with chronic mucocutaneous candidiasis. Could chronic candidiasis lead to esophageal cancer? *Med mycol* 2009;47(2):201-5. doi: 10.1080/13693780802342545
23. Wright NA, Poulson R, Stamp G, Van Noorden S, Sarraf C, Elia G, et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. *Gastroenterology* 1993;104(1):12-20. doi: 10.1016/0016-5085(93)90830-6
24. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011;61(2):69-90. doi: 10.3322/caac.20107
25. Stock M, Otto F. Gene deregulation in gastric cancer. *Gene* 2005;360(1):1-19. doi: 10.1016/j.gene.2005.06.026
26. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55(2):74-108. doi: 10.3322/canjclin.55.2.74

27. Skierucha M, Milne AN, Offerhaus GJA, Polkowski WP, Maciejewski R, Sitarz R. Molecular alterations in gastric cancer with special reference to the early-onset subtype. *World J gastroenterol* 2016;22(8):2460. doi: 10.3748/wjg.v22.i8.2460
28. Thorban S, Böttcher K, Etter M, Roder JD, Busch R, Siewert JR. Prognostic factors in gastric stump carcinoma. *Ann Surg* 2000;231(2):188. doi: 10.1097/00000658-200002000-00006
29. La Vecchia C, Negri E, Gentile A, Franceschi S. Family history and the risk of stomach and colorectal cancer. *Cancer* 1992;70(1):50-5. doi: 10.1002/1097-0142(19920701)70:1<50::aid-cncr2820700109>3.0.co;2-i
30. Ladeiras-Lopes R, Pereira AK, Nogueira A, Pinheiro-Torres T, Pinto I, Santos-Pereira R, et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. *Cancer causes control* 2008;19(7):689-701. doi: 10.1007/s10552-008-9132-y
31. Jedrychowski W, Wahrendorf J, Popiela T, Rachtan J. A case-control study of dietary factors and stomach cancer risk in Poland. *Int J Cancer* 1986;37(6):837-42. doi: 10.1002/ijc.2910370607
32. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 1995;4(2):85-92. doi: Published March 1995
33. Hsing AW, Hansson LE, McLaughlin JK, Nyren O, Blot WJ, Ekbom A, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. *Cancer* 1993;71(3):745-50. doi: 10.1002/1097-0142(19930201)71:3<745::aid-cncr2820710316>3.0.co;2-1
34. Rodríguez-Cuesta J, Hernando FL, Mendoza L, Gallot N, de Cerio AAD, Martínez-de-Tejada G, et al. Candida albicans enhances experimental hepatic melanoma metastasis. *Clin Exp Metastasis* 2010;27(1):35-42. doi: 10.1007/s10585-009-9300-9
35. Malfertheiner P, Megraud F, O'morain C, Gisbert J, Kuipers E, Axon A, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. *Gut* 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288
36. Schulze J, Sonnenborn U. Yeasts in the gut: from commensals to infectious agents. *Dtsch Arztebl Int* 2009;106(51-52):837. doi: 10.3238/arztebl.2009.0837
37. Karczewska E, Wojtas I, Sito E, Trojanowska D, Budak A, Zwolinska-Wcislo M, et al. Assessment of co-existence of helicobacter pylori and candida fungi in diseases of the upper gastrointestinal tract. *J Physiol Pharmacol* 2009;60(Suppl 6):33-9.
38. Von Rosenvinge EC, Song Y, White JR, Maddox C, Blanchard T, Fricke WF. Immune status, antibiotic medication and pH are associated with changes in the stomach fluid microbiota. *The ISME J* 2013;7(7):1354-66. doi: 10.1038/ismej.2013.33
39. Bennett JW, Klich M. Mycotoxins. *Clinical microbiology reviews* 2003;16(3):497-516.
40. Miranda L, Van Der Heijden I, Costa S, Sousa A, Sienna R, Gobara S, et al. Candida colonisation as a source for candidaemia. *Journal of Hospital Infection* 2009;72(1):9-16.
41. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? *Clin Infect Dis* 2001;33(12):1959-67. doi: 10.1086/323759
42. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, et al. CXC chemokines in angiogenesis. *J Leukoc Biol* 2000;68(1):1-8. doi: 10.1189/jlb.68.1.1
43. Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD, Nanney LB, et al. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. *J Leukoc Biol* 2000;67(1):53-62. doi: 10.1002/jlb.67.1.53
44. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. *Cytokine growth factor Rev* 2005;16(6):593-609. doi: 10.1016/j.cytogfr.2005.04.007

45. Ramirez-Garcia A, Arteta B, Abad-Diaz-de-Cerio A, Pellon A, Antoran A, Marquez J, et al. *Candida albicans* increases tumor cell adhesion to endothelial cells in vitro: intraspecific differences and importance of the mannose receptor. *PLoS One* 2013;8(1):e53584. doi: 10.1371/journal.pone.0053584
46. Hostetter MK. An integrin-like protein in *Candida albicans*: implications for pathogenesis. *Trends Microbiol* 1996;4(6):242-6. doi: 10.1016/0966-842X(96)10036-6
47. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. *Nature* 2006;442(7101):461-5. doi: 10.1038/nature04808
48. Langowski JL, Kastelein RA, Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. *Trends Immunol* 2007;28(5):207-12. doi: 10.1016/j.it.2007.03.006
49. Scott B, Jenkins D. Gastro-oesophageal candidiasis. *Gut* 1982;23(2):137-9.
50. Zwolińska-Wcisło M, Budak A, Bogdał J, Trojanowska D, Stachura J. Fungal colonization of gastric mucosa and its clinical relevance. *Med Sci Monit* 2001;7(5):982-88. doi:org/10.1111/j.1439-0507.1998.tb00346.x
51. Wild C, Stewart B, Wild C. World cancer report 2014: World Health Organization Geneva, Switzerland; 2014. doi.org/10.3945%2Fan.116.012211
52. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer 2018. doi.org/10.1002/ijc.31937
53. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *cell* 1990;61(5):759-67. doi: 10.1016/0092-8674(90)90186-i
54. Lynch HT, De la Chapelle A. Hereditary colorectal cancer. *N Engl J Med* 2003;348(10):919-32. doi: 10.1056/NEJMra012242
55. Umar A, Boland CR, Terdiman JP, Syngal S, Chapelle Adl, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Nat Cancer Inst* 2004;96(4):261-8. doi: 10.1093/jnci/djh034
56. SEER S. Explorer: An interactive website for SEER cancer statistics [Internet] Beta Version. *Surveillance Research Program, National Cancer Institute* 2017. <https://seer.cancer.gov/explorer/application.html>
57. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. *Inflamm Bowel Dis* 2013;19(4):789-99. doi: 10.1097/MIB.0b013e31828029c0
58. Yamada A, Komaki Y, Komaki F, Micic D, Zullo S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. *Lancet Oncol* 2018;19(6):758-67. doi: 10.1016/S1470-2045(18)30188-8
59. Lagergren J, Ye W, Ekblom A. Intestinal cancer after cholecystectomy: is bile involved in carcinogenesis? *Gastroenterology* 2001;121(3):542-7. doi: 10.1053/gast.2001.27083
60. Karahalios A, Simpson JA, Baglietto L, MacInnis RJ, Hodge AM, Giles GG, et al. Change in weight and waist circumference and risk of colorectal cancer: results from the Melbourne Collaborative Cohort Study. *BMC cancer* 2016;16(1):157. doi: 0.1186/s12885-016-2144-1
61. O'keefe SJ. Diet, microorganisms and their metabolites, and colon cancer. *Nat Rev Gastroenterol Hepatol* 2016;13(12):691. doi: 10.1038/nrgastro.2016.165
62. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. *JAMA* 2008;300(23):2765-78. doi: 10.1001/jama.2008.839

63. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. *BMJ* 2015;350:g7607. doi: 10.1136/bmj.g7607
64. Nakatsu G, Zhou H, Wu WKK, Wong SH, Coker OO, Dai Z, et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes. *Gastroenterology* 2018;155(2):529-41. e5. doi: 10.1053/j.gastro.2018.04.018
65. Botschuijver S, Roeselers G, Levin E, Jonkers DM, Welting O, Heinsbroek SE, et al. Intestinal fungal dysbiosis is associated with visceral hypersensitivity in patients with irritable bowel syndrome and rats. *Gastroenterology* 2017;153(4):1026-39. doi: 10.1053/j.gastro.2017.06.004
66. Luan C, Xie L, Yang X, Miao H, Lv N, Zhang R, et al. Dysbiosis of fungal microbiota in the intestinal mucosa of patients with colorectal adenomas. *Sci Rep* 2015;5:7980. doi: 10.1038/srep07980
67. Aykut B, Pushalkar S, Chen R, Li Q, Abengoza R, Kim JI, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. *Nature* 2019;574(7777):264-7. doi: 10.1038/s41586-019-1608-2
68. Montoya AM, González GM, Martínez-Castilla AM, Aguilar SA, Franco-Molina MA, Coronado-Cerda E, et al. Cytokines profile in immunocompetent mice during *Trichosporon asahii* infection. *Medical Mycology* 2018;56(1):103-9. doi: 10.1093/mmy/myx018
69. Wu M, Li J, An Y, Li P, Xiong W, Li J, et al. Chitooligosaccharides prevents the development of colitis-associated colorectal cancer by modulating the intestinal microbiota and mycobiota. *Front Microbiol* 2019;10:2101. doi: 10.3389/fmicb.2019.02101
70. Praneenararat S. Fungal infection of the colon. *Clin Exp Gastroenterol* 2014;7:415. doi: 10.2147/CEG.S67776
71. Gao R, Kong C, Li H, Huang L, Qu X, Qin N, et al. Dysbiosis signature of mycobiota in colon polyp and colorectal cancer. *Eur J Clin Microbiol Infect Dis* 2017;36(12):2457-68. doi: 10.1007/s10096-017-3085-6
72. Coker OO, Nakatsu G, Dai RZ, Wu WKK, Wong SH, Ng SC, et al. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. *Gut* 2019;68(4):654-62. doi: 10.1136/gutjnl-2018-317178
73. Ginsburg GS, Willard HF, David SP. Genomic and precision medicine: Primary care: Academic Press; 2017.
74. Dean AG, Kreis R. Understanding lung cancer: presentation, screening, and treatment advances. *The Journal for Nurse Practitioners* 2018;14(4):316-22. doi: 10.1016/j.nurpra.2017.12.014
75. Ross JA, Rosen GD. The molecular biology of lung cancer. *Curr Opin Pulm Med* 2002;8(4):265-9. doi: 10.1097/00063198-200207000-00004
76. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. *J Thorac Oncol* 2015;10(9):1243-60. doi: 10.1097/JTO.0000000000000630
77. Latimer K, Mott T. Lung cancer: diagnosis, treatment principles, and screening. *Am Fam Physician* 2015;91(4):250-6. <https://www.aafp.org/afp/2015/0215/p250.html>
78. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. *Nat Genet* 2005;37(12):1315-6. doi: 10.1038/ng1671

79. Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida A, et al. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. *Ann Oncol* 2014;25(1):138-42. doi: 10.1093/annonc/mdt495
80. O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. *Lancet Oncol* 2011;12(8):795-805. doi: 10.1016/S1470-2045(11)70189-9
81. Meng G, Li Z, Lu G. Pathogenic fungal infection in the lung. *Front Immunol* 2019;10:1524. doi: 10.3389/fimmu.2019.01524
82. Denning DW. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. *J Antimicrob Chemother* 1991;28(suppl_B):1-16. doi: 10.1093/jac/28.suppl_b.1
83. Akinosoglou K, Karkoulas K, Marangos M. Infectious complications in patients with lung cancer. *Eur Rev Med Pharmacol Sci* 2013;17(1):8-18.
84. Ping-López R, Pavón SR. Talaromycosis in a Lung Cancer Patient: A Rare Case. *Cureus* 2020;12(9). doi: 10.7759/cureus.10615
85. Watanabe H, Shirai T, Saigusa M, Asada K, Arai K. Subacute invasive pulmonary aspergillosis after chemoradiotherapy for lung cancer. *Respirol Case Rep* 2020;8(2):e00523. doi: 10.1002/rcr2.523
86. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. *Lancet Glob Health* 2020;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6
87. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. *Ann Oncol* 2011;22(12):2675-86. doi: 10.1093/annonc/mdr015
88. Kasakura Y, Phan A, Ajani J. Adjuvant therapy for resected gastric carcinoma. *Surg Oncol Clin N Am* 2002;11(2):431-44, xii-xiii. doi: 10.1016/s1055-3207(02)00009-1
89. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. *Int J cancer* 1999;83(1):18-29. doi: 10.1002/(sici)1097-0215(19990924)83:1<18::aid-ijc5>3.0.co;2-m
90. Delam H, Izanloo S, Bazrafshan M-R, Eidi A. Risk factors for cervical cancer: An epidemiological review. *J Health Sci Surveillance Sys* 2020;8(3):105-9. doi: 10.30476/JHSS.2020.86539.1092
91. Godoy-Vitorino F, Romaguera J, Zhao C, Vargas-Robles D, Ortiz-Morales G, Vázquez-Sánchez F, et al. Cervicovaginal fungi and bacteria associated with cervical intraepithelial neoplasia and high-risk human papillomavirus infections in a hispanic population. *Front microbiol* 2018;9:2533. doi: 10.3389/fmicb.2018.02533
92. Moradi S, HASANI MT, Darvish L, Roozbeh N. Evaluating Cervicovaginal Infections and Cervical Cancer in Women with Low Socioeconomic Levels. *Iran J Public Health* 2017;46(6):867.
93. Neves RP, de Lima Neto RG, Leite MC, da Silva VKA, dos Santos FdAG, Macêdo DPC. *Cryptococcus laurentii* fungaemia in a cervical cancer patient. *Braz J Infect Dis* 2015;19(6):660-3. doi: 10.1016/j.bjid.2015.06.014
94. Katalinic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). *Br J Dermatol* 2003;149(6):1200-6. doi: 10.1111/j.1365-2133.2003.05554.x

95. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020;70(1):7-30. doi: 10.3322/caac.21590
96. Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. *Dermatol Ther (Heidelb)* 2017;7(1):5-19. doi: 10.1007/s13555-016-0165-y
97. DeVita VT, Lawrence TS, Rosenberg SA. Cancer of the skin: Cancer: Principles & practice of oncology: Lippincott Williams & Wilkins; 2015.
98. Bodey GP. Fungal infections complicating acute leukemia. *J Chronic Dis* 1966;19(6):667-87. doi: 10.1016/0021-9681(66)90066-x
99. Bast Jr RC, Croce CM, Hait WN, Hong WK, Kufe DW, Piccart-Gebart M, et al. Holland-frei cancer medicine cloth: John Wiley & Sons; 2017.
100. Ferrándiz-Pulido C, Martín-Gómez MT, Repiso T, Juárez-Dobjanschi C, Ferrer B, López-Lerma I, et al. Cutaneous infections by dematiaceous opportunistic fungi: Diagnosis and management in 11 solid organ transplant recipients. *Mycoses* 2019;62(2):121-7. doi: 10.1111/myc.12853
101. Brothers RP, Daveluy SD. Squamous cell carcinoma mimicking fungal infection. *IDCases* 2016;6:72-3. doi: 10.1016/j.idcr.2016.09.016
102. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: A national resource. *Cancer Epidemiol Biomarkers Prev* 1999;8(12):1117-21. doi: Published December 1999
103. Vargas A. Natural history of ovarian cancer. *Ecancermedicalscience* 8: 465. 2014. doi: 10.3332/ecancer.2014.465
104. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. *CA Cancer J Clin* 2016;66(2):115-32. doi: 10.3322/caac.21338
105. Howlader N. Seer cancer statistics review, 1975-2008, national cancer institute, Bethesda, md. http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site 2011.
106. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. *Best Prac Res Clin Obstet Gynaecol* 2006;20(2):207-25. doi: 10.1016/j.bpobgyn.2005.10.007
107. Casagrande J, Pike M, Ross R, Louie E, Roy S, Henderson B. "Incessant ovulation" and ovarian cancer. *The Lancet* 1979;314(8135):170-3. doi: 10.1016/s0140-6736(79)91435-1
108. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. *J Natl Cancer Inst* 1983;71(4):717-21. doi.org/10.1093/jnci/71.4.717
109. Slatnik CL, Duff E. Ovarian cancer: Ensuring early diagnosis. *Nurse Pract* 2015;40(9):47-54. doi: 10.1097/01.NPR.0000450742.00077.a2
110. Huang X, Wang X, Shang J, Lin Y, Yang Y, Song Y, et al. Association between dietary fiber intake and risk of ovarian cancer: a meta-analysis of observational studies. *J Int Med Res* 2018;46(10):3995-4005. doi: 10.1177/0300060518792801
111. Schottenfeld D, Winawer S. Cancers of the large intestine. *Cancer Epidemiol Prev* 1996;2:813-40. doi: 10.1093/acprof:oso/9780195149616.001.0001
112. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* 2008;371(9612):569-78. doi: 10.1016/S0140-6736(08)60269-X
113. Beral V, Gaitskell K, Hermon C. Collaborative Group on Epidemiological Studies of Ovarian Cancer CG on ES of O. et al. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. *Lancet Oncol* 2012;13(9):946-56. doi: 10.1016/S1470-2045(12)70322-4

114. Beral V, Gaiatskell K, Hermon C. Collaborative Group on Epidemiological Studies of Ovarian Cancer CG on ES of O. et al. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. *Lancet Oncol* 2012;13(9):946-56. doi: 10.1016/S1470-2045(12)70322-4
115. Banerjee S, Tian T, Wei Z, Shih N, Feldman MD, Alwine JC, et al. The ovarian cancer oncobiome. *Oncotarget* 2017;8(22):36225. doi: 10.18632/oncotarget.16717
116. Yang CS. Research on esophageal cancer in china: A review. *Cancer Res* 1980;40(8 Part 1):2633-44. doi: Published August 1980
117. Ribeiro Jr U, Posner MC, Safatle-Ribeiro AV, Reynolds JC. Risk factors for squamous cell carcinoma of the oesophagus. *Br J Surg*. 1996 Sep;83(9):1174-85.. doi.org/10.1046/j.1365-2168.1996.02421.x
118. Li M, Lu S, Ji C, Wang M, Cheng S, Jin C. Formation of carcinogenic n-nitroso compounds in corn-bread inoculated with fungi. *Scientia Sinica* 1979;22(4):471-7.
119. Meredith FI. [37] isolation and characterization of fumonisins. *Methods Enzymol* 2000. p. 361-73. doi: 10.1016/s0076-6879(00)11096-1
120. Ikoma T, Tsuchiya Y, Asai T, Okano K, Ito N, Endoh K, et al. Ochratoxin a contamination of red chili peppers from chile, bolivia and peru, countries with a high incidence of gallbladder cancer. *Asian Pac J Cancer Prev* 2015;16(14):5987-91. doi: 10.7314/apjcp.2015.16.14.5987
121. Kothavade RJ, Kura M, Valand AG, Panthaki M. Candida tropicalis: Its prevalence, pathogenicity and increasing resistance to fluconazole. *J Med Microbiol* 2010;59(8):873-80. doi: 10.1099/jmm.0.013227-0
122. Gupta N, Chaudhary A, Talwar P. Candidial obstruction of the common bile duct. *Br J Surg* 1985;72(1). doi.org/10.1002/bjs.1800720106
123. Wise GJ, Shteynshlyuger A. How to diagnose and treat fungal infections in chronic prostatitis. *Curr Urol Rep* 2006;7(4):320-8. doi.org/10.1007/s11934-996-0012-2
124. Banerjee S, Tian T, Wei Z, Shih N, Feldman MD, Peck KN, et al. Distinct microbial signatures associated with different breast cancer types. *Front microbiol* 2018;9:951. doi: 10.3389/fmicb.2018.00951

Table 1. The latest clinical finding and the association of fungal infections with versatile cancers.

Cancer type	Fungal agents	References	
Esophageal cancer	<i>Candida</i> sp.	<i>C. albicans</i> <i>C. glabrata</i> <i>C. tropicalis</i> <i>C. krusei</i> <i>C. parepsilosis</i>	16 116
	<i>Torulopsis</i> sp.	<i>T. glabrata</i> , <i>T. tomatata</i>	17,117,118
	<i>Aspergillus</i> sp.	<i>A. flavus</i> , <i>A. parasiticus</i>	18-20,119
	<i>Fusarium</i> sp.	<i>F. verticillioides</i> , <i>F. proliferation</i>	
Gastric cancer	<i>C. albicans</i> <i>Phialemonium</i> spp. <i>Aspergillus</i> spp., <i>Penicillium</i> spp., <i>Fusarium</i> spp.		37 38 39
	<i>S. cerevisiae</i> , <i>Malassezia</i> spp., <i>Mucor</i> spp., <i>Cryptococcus</i> spp., <i>Rhodotorula</i> spp., <i>Trichosporon</i> spp., <i>Histoplasma</i> spp., <i>Coccidioides</i> spp., <i>Paracoccidioides</i> spp. and <i>Blastomyces</i> spp		40,41
Gallbladder cancer	<i>Aspergillus</i> sp.	<i>A. flavus</i> , <i>A. parasiticus</i>	39
	<i>Penicillium</i>		120,121
	<i>Candida</i> sp.	<i>C. albicans</i> , <i>C. glabrata</i> , <i>C. tropicalis</i>	122
Colorectal cancer	<i>Blastomyces dermatitidis</i> , <i>Cryptococcus neoformans</i>		51
	<i>C. tropicalis</i> , <i>C. albicans</i> , <i>Phoma</i> , <i>Malassezia</i> , <i>Trichosporon</i> , <i>Cladosporium</i> <i>Paracoccidioides</i> , <i>Histoplasma</i> , <i>Cryptococcus</i> , <i>Aspergillus</i> , <i>Penicillin</i> , <i>Zygomycetes</i> , <i>Pneumocystis</i> , <i>Scedosporis</i>		66-69

	<i>Rhodotorula, Thanatephorum, Plectosphaerella</i>	70	
	<i>A. flavus, Kwoniella mangrovensis, Pseudogymnoascus sp., Debaryomyces fabryi, A. sydowii, Moniliophthora perniciosa, K. heavenensis, A. ochraceoroseus, Talaromyces islandicus, Malassezia globosa,</i>	66 72	
Colorectal cancer	<i>Pseudogymnoascus sp., A. rambellii, Pneumocystis murina, Nosemia apis, Malassezia, Moniliophthora, Rhodotorula, Acremonium, Thielaviopsis, Pisolithus</i>	72	
Lung cancer	<i>Aspergillus sp., Cryptococcus sp., Pneumocystis sp.</i>	81	
	<i>Trichosporon, Fusarium, Rhizopus, Histoplasma capsulatum, H. immitis, P. jiroveci</i>	83	
	<i>T. marneffe</i>	84	
	<i>A. fumigatus</i>	85	
Prostate cancer	<i>Candida sp., Aspergillus sp., C. neoformans, C. immitis, H. capsulatum, B. dermatitidis</i>	123	
Cervical cancer	<i>Candida, Malassezia, Sporidiobolaeae, Saccharomyces, Nakaseomyces, Gjaerumia, Pleosporales</i>	91	
	<i>Cryptococcus laurentii</i>	93	
Skin cancer	<i>C. neoformans, H. capsulatum, C. immitis, Trichosporon spp., Mucor, Fusarium, Rhizopus</i>	99	
	<i>Candida sp.</i>	<i>C. albicans, C. tropicalis, C. glabrata, C. parapsilosis</i>	99
	<i>A. alternata, A. infectoria, C. cladosporioides, M. arundinis, E. oligosperma</i>	100	
Breast cancer	<i>Aspergillus, Candida, Coccidioids, Cunninghamella, Geotrichum, Pleistophora, Rhodotorula, Filobasidiella, Mucor, Trichophyton, Epidermophyton, Fonsecaea, Psuedallescheria, Penicillium, Ajellomyces, Alternaria, Rhizomucor, Piedraia, Malassezia</i>	124	
Ovarian cancer	<i>Pneumocystis, Acremonium, Cladophialophora, Malassezia, Microsporidia Pleistophora, Ajellomyces, Aspergillus, Candida, Cladosporium, Coccidioides, Cryptococcus, Cunninghamella, Issatchenkia, Nosema, Paracoccidioides, Penicillium, Pleistophora, Rhizomucor, Rhizopus, Rhodotorula, Trichophyton</i>	115	

Figures legends:




Figure 1.

Figure 1. Different types of risk factors in carcinogenesis.




Figure 2.

Figure 2. Different studied fungal genera and species in carcinogenesis.